Latest filings (excl ownership)
15-12G
Securities registration termination
23 Jan 23
EFFECT
Notice of effectiveness
17 Jan 23
25-NSE
Exchange delisting
11 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jan 23
POS AM
Prospectus update (post-effective amendment)
11 Jan 23
8-K
Completion of Acquisition or Disposition of Assets
11 Jan 23
SC 14D9/A
Tender offer solicitation (amended)
11 Jan 23
SC TO-T/A
Third party tender offer statement (amended)
11 Jan 23
SC 14D9/A
Tender offer solicitation (amended)
3 Jan 23
SC TO-T/A
Third party tender offer statement (amended)
21 Dec 22
SC 14D9/A
Tender offer solicitation (amended)
21 Dec 22
8-K
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022
12 Dec 22
SC 14D9
Tender offer solicitation
12 Dec 22
SC TO-T
Third party tender offer statement
12 Dec 22
SC14D9C
Written communication relating to third party tender offer
21 Nov 22
SC TO-C
Information about tender offer
21 Nov 22
8-K
Form of Tender and Support Agreement
21 Nov 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
Imago BioSciences Reports Third Quarter 2022 Financial
9 Nov 22
8-K
Departure of Directors or Certain Officers
1 Sep 22
EFFECT
Notice of effectiveness
30 Aug 22
424B5
Prospectus supplement for primary offering
29 Aug 22
CORRESP
Correspondence with SEC
25 Aug 22
UPLOAD
Letter from SEC
19 Aug 22
8-K
Other Events
18 Aug 22
S-3
Shelf registration
18 Aug 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
8-K
Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
12 Aug 22
8-K
Regulation FD Disclosure
13 Jun 22
8-K
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022
10 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
6 Jun 22
10-Q
2022 Q1
Quarterly report
12 May 22
8-K
Imago BioSciences Reports First Quarter 2022 Financial Results and Provides Recent Business Updates
12 May 22
8-K
Regulation FD Disclosure
12 May 22
8-K
Regulation FD Disclosure
9 May 22
8-K
Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia
3 May 22
DEFA14A
Additional proxy soliciting materials
19 Apr 22
DEF 14A
Definitive proxy
19 Apr 22
S-8
Registration of securities for employees
24 Mar 22
Latest ownership filings
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 23
SC 13G/A
Farallon Capital Partners, L.P.
1 Feb 23
SC 13G/A
BlackRock Inc.
26 Jan 23
SC 13G/A
BlackRock Inc.
20 Jan 23
SC 13D/A
Clarus Lifesciences III, L.P.
12 Jan 23
4
LAURIE KEATING
11 Jan 23
4
Enoch Kariuki
11 Jan 23
4
Amy E. Tapper
11 Jan 23
4
Hugh Rienhoff JR
11 Jan 23
4
Laura G. Eichorn
11 Jan 23
4
DENNIS HENNER
11 Jan 23
4
Michael Arenberg
11 Jan 23
4
Moghrabi Dina Chaya
11 Jan 23
4
Hsiangyi Chiang
11 Jan 23
4
Jennifer Peppe
11 Jan 23
4
Robert Jr. Baltera
11 Jan 23
4
Hsiangyi Chiang
5 Jan 23
4
Michael Arenberg
5 Jan 23
4
Jennifer Peppe
5 Jan 23
4
Laura G. Eichorn
5 Jan 23
4
Amy E. Tapper
5 Jan 23
4
Hugh Rienhoff JR
5 Jan 23
4
Laura G. Eichorn
29 Dec 22
4
Michael Arenberg
29 Dec 22
4
Amy E. Tapper
20 Dec 22
4
Michael Arenberg
20 Dec 22
4
Jennifer Peppe
19 Dec 22
4
Jennifer Peppe
19 Dec 22
4
Hugh Rienhoff JR
19 Dec 22
4
Laura G. Eichorn
19 Dec 22
SC 13G/A
FMR LLC
12 Dec 22
4
Amy E. Tapper
14 Nov 22
4
Michael Arenberg
14 Nov 22
4
Hsiangyi Chiang
14 Nov 22
4
Jennifer Peppe
14 Nov 22
4
Laura G. Eichorn
14 Nov 22
4
Hugh Rienhoff JR
14 Nov 22
SC 13D/A
Frazier Healthcare VII, L.P.
14 Nov 22
4
Amy E. Tapper
4 Nov 22
4
Laura G. Eichorn
4 Nov 22